Obsidian Therapeutics

Obsidianites from near and far gathered to celebrate summer and give back – building bikes for local youth through The Leaders Institute in support of the Boys & Girls Club of Metro North. The eight bicycles our teams assembled were donated to kids in our Greater Boston community. It was an afternoon filled with teamwork, laughter, good food, and the unmistakable energy of Obsidianites in action. #obsidianrocks

Congratulations to Mercay Reuter, Billy Blanco, J. Isaac Godfroy, Todd Hawley Ph.D, RAC, and Caroline Code on their recent promotions! Thank you all for the value you bring every day and the positive impact you have had thus far. We look forward to your continued growth and success! #promotions #Obsidianrocks

We are excited to share the story of a patient who participated in a TIL cell therapy clinical trial, which was produced for Obsidian in collaboration with UofL Health by BBC StoryWorks Commercial Productions.   #ObsidianRocks #TIL #TheNextFrontier https://lnkd.in/gcdy_Y_p   Note that our therapy remains investigational and in development.

As we conclude another Co-Op cycle, we want to extend our gratitude to our Northeastern University Winter Co-Ops and their mentors. We have been fortunate to collaborate with an exceptional group of Co-Ops: Hansini, Preet, Jennifer, Rohan, Ankita, Samantha, Izak, and Lindsey. A special thank you goes out to our dedicated mentors Zheng, Carmela, Billy, Tyesha, Sanika, Erin, Paul, Trisha, and Alfredo! We wish our Co-ops much success in their future pursuits! #Co-Ops #mentors #Northeastern #obsidianrocks

We are excited to share that today at #ASCO2025 we will be presenting positive clinical data from OBX-115 in patients with advanced melanoma in the ongoing Agni-01 multicenter study. OBX-115 maintains a consistent efficacy profile without IL2 and with low-dose lymphodepletion: OBX-115 ORR was 67% at recommended Phase 2 dose (n=6). OBX-115 continues to demonstrate a positively differentiated safety profile relative to IL2-dependent non-engineered TIL cell therapy: no DLTs, no treatment-related ICU transfer, no treatment-related mortality. Learn more here: https://lnkd.in/eXc2i7YM

Obsidian Therapeutics continued our tradition of celebrating AAPI Heritage Month by exploring culinary traditions and their cultural significance with cooking lessons and lunch prepared by our colleagues. Special thanks to Gauri and Nirzari for teaching us to make samosas, and to Natasha for her lesson on making banh mi. Sharing a meal is always a great connector, and the added cultural insights enriched our appreciation. #AAPI #diversity #obsidianrocks

The Obsidian Therapeutics team made a strong showing to support the Melanoma Research Foundation’s (MRF) Miles for Melanoma 5K in Boston on May 10. Like us, MRF holds patients at the center of all they do. It was an inspiring day and we’re proud to contribute to their work supporting research, education, and advocacy for the melanoma community. #MelanomaAwarenessMonth #MelanomaResearchFoundation #obsidianrocks

We are excited to announce publication of a Molecular Therapy manuscript titled, “IL2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL15.” This article describes the preclinical development of our lead product candidate, OBX-115: #TIL engineered with membrane-bound IL15 fused to a drug-responsive domain (DRD) that is regulated by the FDA-approved small-molecule drug acetazolamide. You can read the manuscript here: https://lnkd.in/eXEQ95eV.

We’re excited to announce an upcoming presentation at #ASGCT 2025!   We will present preclinical data on novel applications of our cytoDRiVE platform, whereby regulation of an artificial transcription factor is used to enable gene-ON and gene-OFF states with ligand binding. This approach unlocks numerous additional applications for cytoDRiVE, including the ability to regulate secreted proteins and expression of mRNA or siRNA.   Learn more here: https://lnkd.in/ePYTBFsh

We’re excited to announce the publication of 3 abstracts for poster presentations at #AACR 2025! In addition to a trial-in-progress study design update on the ongoing multicenter study Agni-01, we will share preclinical data from our cytoDRiVE® platform demonstrating spatiotemporal regulation of membrane-bound IL12 in syngeneic solid tumor models and preclinical data on OBX-115 TIL phenotype starting from NSCLC tumor tissue. Learn more here: https://lnkd.in/ectdRBtt